ESMO26: Wider use of breast cancer gene test could save NHS £4m annually

Veracyte's Prosigna, a gene test that identifies breast cancer patients who can forgo chemotherapy, could expand NHS use to save approximately £4 million annually, according to findings presented at ESMO26. The test determines treatment eligibility by assessing recurrence risk, potentially reducing unnecessary chemotherapy exposure while maintaining outcomes.